Publications by authors named "Derek R White"

N-linked glycosylation is a common post-translational modification that has various effects on multiple types of proteins. The extent to which an N-linked glycoprotein is modified and the identity of glycans species involved is of great interest to the biopharmaceutical industry, since glycosylation can impact the efficacy and safety of therapeutic monoclonal antibodies (mAbs). mAbs lacking core fucose, for example, display enhanced clinical efficacy through increased antibody-dependent cellular cytotoxicity.

View Article and Find Full Text PDF
Article Synopsis
  • Biosimilars like Acellbia® are expected to lower prices and improve access to effective biologic therapies, but there are still concerns about their similarity to original products and the availability of comparative data.
  • A study was conducted comparing the innovator drug Rituxan® with the Russian biosimilar Acellbia® using advanced mass spectrometry techniques.
  • The findings revealed that while the two products were generally similar, Acellbia® showed differences in glycosylation patterns that enhanced its biological activity, indicating potential advantages over Rituxan®.
View Article and Find Full Text PDF

A series of well-defined N-glycosylated IgG4-Fc variants were utilized to investigate the effect of glycan structure on their physicochemical properties (conformational stability and photostability) and interactions with an Fc γ receptor IIIA (FcγRIIIA). High mannose (HM, GlcNAcMan [n = 0-4]), Man (GlcNAcMan), GlcNAc, and N297Q IgG4-Fc were prepared in good quality. The physical stability of these IgG4-Fc variants was examined with differential scanning calorimetry and intrinsic fluorescence spectroscopy.

View Article and Find Full Text PDF

Multiple sclerosis (MS) is a neurodegenerative disease that is estimated to affect over 2.3 million people worldwide. The exact cause for this disease is unknown but involves immune system attack and destruction of the myelin protein surrounding the neurons in the central nervous system.

View Article and Find Full Text PDF

Four different well-defined IgG1 Fc glycoforms are proposed as a model system to examine important biological and physicochemical features for protein drug biosimilar analyses. The IgG1 Fc glycoforms were produced by yeast expression combined with in vitro enzymatic synthesis as a series of sequentially truncated high-mannose IgG1 Fc glycoforms with an anticipated range of biological activity and structural stability. Initial characterization with mass spectrometry, SDS-PAGE, size exclusion HPLC, and capillary isoelectric focusing confirmed that the glycoproteins are overall highly similar with the only major difference being glycosylation state.

View Article and Find Full Text PDF